### UNITED STATES PATENT AND TRADEMARK OFFICE

## BEFORE THE PATENT TRIAL AND APPEAL BOARD

SAMSUNG BIOEPIS CO., LTD., CELLTRION INC, and BIOCON BIOLOGICS INC.

Petitioner,

v.

REGENERON PHARMACEUTICALS, INC. Patent Owner.

Patent No. 11,253,572

\_\_\_\_\_\_

Inter Partes Review No. IPR2023-008841

PATENT OWNER'S UPDATED EXHIBIT LIST

<sup>&</sup>lt;sup>1</sup> IPR2024-00260 and IPR2024-00298 are joined with IPR2023-00884.



# Updated Exhibit List for Inter Partes Review of U.S. Patent No. 11,253,572


Exhibit No.	Exhibit Description
2001	Expert Declaration of Richard Manning, Ph.D., Mylan Pharms.
	Inc. v. Regeneron Pharms., Inc., IPR2021-00881, Ex. No. 2052
	(Feb. 11, 2022)
2002	EYLEA® Label (rev. Oct. 2014)
2003	Trial Transcript (unsealed portions), Regeneron Pharms., Inc. v. Mylan Pharms. Inc., No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.)
2004	Press Release, Positive Interim Phase 2 Data Reported for VEGF
	Trap-Eye in Age-Related Macular Degeneration, Regeneron
	Pharmaceuticals, Inc. (Mar. 27, 2007)
2005	Email from George Yancopoulos to Murray Goldberg re Top Line sum for PR (Mar. 22, 2007)
2006	Interim Analysis of Phase 2 Study of VEGF Trap in AMD patients
	(Mar. 22, 2007) (Attachment to Ex.2005)
2007	George D. Yancopoulos, VEGF Trap: Scientific Background,
	BSP / REGN Kick-Off (Feb. 16, 2007)
2008	Email from Kathleen Lawrence re Decisions & Actions: AMD
	Ph3 Program Mtg – 4/2/07 (Apr. 2, 2007)
2009	Email from George Yancopoulos to Darlene Jody re Summary of
	issues for call: AMD P3 Planning with enclosed outline attached
	(Apr. 4, 2007)
2010	Email from Robert Terifay to George Yancopoulos re VGTeye
	VIEW 430 presentation (Nov. 19, 2010)
2011	Vascular Endothelial Growth Factor (VEGF) Trap-Eye:
	Investigation of Efficacy and Safety in Wet Age-Related Macular
	Degeneration (AMD) - VIEW 1 and VIEW 2 – 1-Year Results
	(Attachment to Ex.2010)
2012	Regeneron Pharmaceuticals, <i>Phase 1 Study of VEFT Trap in</i>
	Patients With Diabetic Macular Edema,
	https://clinicaltrials.gov/study/NCT00320814 (last updated Jun.
	10, 2011)
2013	Regeneron, Clinical Study Concept - Ophthalmology-Diabetic
	Macular Edema-Phase 2-IVT-VGFT-OD-0706 (updated May 19,
	2008)
2014	Diana V. Do et al., One-Year Outcomes of the DA VINCI Study of
	VEGF Trap-Eye in Eyes with Diabetic Macular Edema, 119
	OPHTHALMOLOGY 1658-1665 (Aug. 2012).



A L A R M Find authenticated court documents without watermarks at docketalarm.com.

## IPR2023-00884

Exhibit No.	Exhibit Description
2015	DA VINCI – DME And VEGF Trap-Eye: Investigation of Clinical
2013	Impact: One Year Data (Dec. 8, 2010) (attachment to Ex.2024)
2016	Regeneron Pharmaceuticals, DME And VEGF Trap-Eye
2010	[Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)]
	Investigation of Clinical Impact (DA VINCI),
	https://clinicaltrials.gov/study/NCT00789477 (last updated Sep. 9,
	2014)
2017	Email from Caroline Saxton re Data Review (Feb. 1, 2010)
2018	Regeneron Pharmaceuticals, Inc., VGFT-OD-0706 Week 24
	Topline Results (Feb. 1, 2010) (attachment to Ex.2017)
2019	DRAFT – DA VINCI – 6-Month Primary Endpoint (Feb. 1, 2010)
	(attachment to Ex.2017)
2020	Regeneron Pharmaceuticals, Inc., VEGF Trap-Eye Shows Positive
	Results in a Phase 2 Study in Patients With Diabetic Macular
	Edema (Feb. 18, 2010)
2021	Email from Alyson Berliner to Dave Brown re ARVO late
	breakers (Mar. 1, 2010)
2022	DA VINCI: DME And VEGF Trap-Eye: Investigation of Clinical
	Impact: Phase 2 study in patients with Diabetic Macular Edema
	(DME) (Mar. 1, 2010) (Attachment to Ex.2021)
2023	Email from Dave Brown to Alyson Berliner and James Major re
	ARVO abstract (Mar. 3, 2010)
2024	Email from Caroline Saxton re Slides and tables – DaVinci (Dec.
	8, 2010)
2025	U.S. Provisional Patent Application No. 61/434,836 (Jan. 21,
	2011)
2026	Mylan Pharmaceuticals Inc.'s Answer, Defenses, and
	Counterclaims to Plaintiff's Complaint, Regeneron Pharms., Inc. v.
	Mylan Pharms. Inc., No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.),
2025	ECF No. 47 (filed Aug. 25, 2022)
2027	Stipulation and Order Joining Biocon Biologics Inc. as Defendant,
	Regeneron Pharms., Inc. v. Mylan Pharms. Inc., No. 1:22-cv-
2020	00061-TSK-JPM (N.D.W. Va.), ECF No. 523 (filed Jun. 5, 2023)
2028	Complaint for Patent Infringement, Regeneron Pharms., Inc. v.
	Mylan Pharms. Inc., No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.),
	ECF No. 1 (filed Aug. 2, 2022)



## IPR2023-00884

Exhibit No.	Exhibit Description
2029	Order on Claim Construction, Regeneron Pharms., Inc. v. Mylan
	Pharms. Inc., No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF
	No. 427 (filed Apr. 19, 2023)
2030	Scheduling Order, Regeneron Pharms., Inc. v. Mylan Pharms.
	<i>Inc.</i> , No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF No. 87 (filed Oct. 25, 2022)
2031	Regeneron's Stipulation Regarding Summary Judgment and Case
	Narrowing, Regeneron Pharms., Inc. v. Mylan Pharms. Inc., No.
	1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF No. 433 (filed Apr.
	27, 2023)
2032	Defendant's Opening Post Trial Brief - Issues Where Defendants
	Bear the Burden of Proof, Regeneron Pharms., Inc. v. Mylan
	Pharms. Inc., No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.), ECF
2022	No. 576 (filed July 7, 2023)
2033	Order Setting Briefing Schedule, <i>Regeneron Pharms., Inc. v. Mylan Pharms. Inc.</i> , No. 1:22-cv-00061-TSK-JPM (N.D.W. Va.),
	ECF No. 514 (filed May 30, 2023)
2034	Transcript of the Status Conference held on Sept. 28, 2022,
2031	Regeneron Pharms., Inc. v. Mylan Pharms. Inc., No. 1:22-cv-
	00061-TSK-JPM (N.D.W. Va.), ECF No. 90 (filed Nov. 2, 2022)
2035	Email from George Yancopoulos re DME Phase 2 – ALL
	TABLES (Feb. 2, 2010)
2036	DME Target Product Profile - VEGF Trap-Eye (Sept. 26, 2007)
2037	Clinical Development & Regulatory Affairs Weekly Update (Oct.
	29, 2010)
2038	Clinical Development & Regulatory Affairs Weekly Update (Dec.
	3, 2010)
2039	Email from George Yancopoulos re DME PLANS & FDA
20.40	meeting pre-discussion (Jan. 9, 2008)
2040	MEMO re Guidance From Bayer/ REGN Sr. Management
	Regarding Additional Indications in Ophthalmology from George
	Yancopoulos to Bayer/REGN Joint Development Group (Mar. 28, 2008)
2041	Action Items by GD Yancopoulos - Bayer/REGN JSC (Feb. 15,
2071	2008)
2042	Email from Yuhwen Soo to George Yancopoulos re Can you send
2012	me that slide you made combining the VA curves for View1 &
	View2 (Nov. 20, 2010)




Exhibit No.	Exhibit Description
2043	Vascular Endothelial Growth Factor (VEGF): Investigation of
	Efficacy and Safety in Wet Age-Related Macular Degeneration
	(AMD)—VIEW1 + VIEW 2: 1-Year Results (Nov. 20, 2010)
2044	(Attachment to Ex.2042)
2044	Email from Michael Aberman to George Yancopoulos and
2045	Leonard Schleifer re Press Release (Nov. 19, 2010)
2045	Regeneron, Bayer and Regeneron Report Positive Top-Line  Regults of Two Phase 2 Studies with VECE Trap Eve in Wet Age
	Results of Two Phase 3 Studies with VEGF Trap-Eye in Wet Agerelated Macular Degeneration (Nov. 19, 2010) (Attachment to
	Ex.2044)
2046	U.S. Food & Drug Administration, 22 Case Studies Where Phase
2010	2 and Phase 3 Trials Had Divergent Results (Jan. 2017)
2047	VEGF Trap-Eye in Wet AMD - CLEAR-IT 2: Summary of One-
	Year Key Results, Presented at 2008 Retina Society Meeting,
	Scottsdale, Arizona (Sep. 28, 2008)
2048	Regeneron Pharmaceuticals, Inc., A Double-Masked, Randomized,
	Controlled Study of the Safety, Tolerability and Biological Effect
	of Repeated Intravitreal Administration of VEGF Trap-Eye in
	Patients with Diabetic Macular Edema (DME) (Issued Jan. 28,
	2009)
2049	Appendix to Heier et al., Intravitreal Aflibercept (VEGF Trap-
	Eye) in Wet Age-Related Macular Degeneration, 119
	OPHTHALMOLOGY 2537 (2012)
2050	Retinal Physician Symposium Covers Broad Range of Topics,
	Retinal Physician (Sept. 1, 2006),
	https://www.retinalphysician.com/issues/2006/september2006/reti
2051	nal-physician-symposium-covers-broad-range-of
2051	Prema Abraham et al., Randomized, Double-Masked,
	ShamControlled Trial of Ranibizumab for Neovascular Age-
	Related Macular Degeneration: PIER Study Year 2, 150 AM. J.
2052	OPHTHALMOLOGY 315 (2010)
2052	FDA, Step 3: Clinical Research, https://www.fda.gov/patients/drug-development-process/step-3-
	clinical-research (last accessed Aug. 23, 2023)
2053	Prosecution History of U.S. Patent App. No. 16/159,282 B2
2054	Anant Pai et al., Current concepts in intravitreal drug therapy for
2037	diabetic retinopathy, 24 SAUDI J. OPHTHALMOLOGY 143 (June 30,
	2010)



# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

# **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

# **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

# **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

#### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

